Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Rg3039 (PF-06687859) is a potent DcpS inhibitor. DcpS is a therapeutic target for spinal muscular atrophy. Spinal muscular atrophy (SMA) is caused by deletion or mutation of both copies of the SMN1 gene which produces an essential protein known as SMN. RG3039 improves motor function in SMA mice. RG3039 also showed activity to improve survival, function and motor unit pathologies in two SMA mouse models.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 32.00 | |
5 mg | In stock | $ 51.00 | |
10 mg | In stock | $ 84.00 | |
25 mg | In stock | $ 165.00 | |
50 mg | In stock | $ 272.00 | |
100 mg | In stock | $ 438.00 | |
500 mg | In stock | $ 985.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 57.00 |
Description | Rg3039 (PF-06687859) is a potent DcpS inhibitor. DcpS is a therapeutic target for spinal muscular atrophy. Spinal muscular atrophy (SMA) is caused by deletion or mutation of both copies of the SMN1 gene which produces an essential protein known as SMN. RG3039 improves motor function in SMA mice. RG3039 also showed activity to improve survival, function and motor unit pathologies in two SMA mouse models. |
Targets&IC50 | DcpS:0.069 nM. |
Synonyms | PF-06687859 |
Molecular Weight | 432.35 |
Formula | C21H23Cl2N5O |
CAS No. | 1005504-62-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 0.1 mg/mL (insoluble)
DMSO: 6 mg/mL (13.88 mM), Sonication and heating are recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Rg3039 1005504-62-0 Others PF-06687859 PF06687859 Inhibitor inhibit PF 06687859 Rg-3039 RG 3039 inhibitor